BLENREP is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

For the full prescribing information, including BOXED WARNING, visit: www.BLENREPREMS.com

Banner Image

About BCMA

BCMA, B-cell maturation antigen, is a transmembrane glycoprotein which is universally expressed in plasma cells and is the principal ligand responsible for growth and uncontrolled proliferation of multiple myeloma cells.

About CMA

CMA, cell-mediated cytotoxicity, can lead to cell death when antibodies targeted to cell surface antigens are bound to the target cells and internalized into the immune effector cells.

Mechanism of Action

BLENREP employs a multi-targeted mechanism of action that is directed toward BCMA.

BLENREP is the first anti-BCMA ADC approved for the treatment of adult patients with relapsed or refractory multiple myeloma based on demonstrated clinical benefit in confirmatory trials. BLENREP is the first BCMA-targeted therapy approved in the US and EU.

Background Information for BLENREP (belantamab mafodotin-blmf)

BLENREP (belantamab mafodotin-blmf) is a monoclonal antibody conjugated with a maytansinoid payload. The conjugate consists of a CD38-specific antibody, belantamab mafodotin, linked to an maytansinoid (blmf).

Important Safety Information

Of the 218 patients who received BLENREP in DREAMM-2, 43% were aged 65 to less than 75 years and 6% were aged 75 years and older. The most common adverse reactions (≥20%) were keratopathy (71%), decreased visual acuity (53%), nausea (24%), blurred vision (21%), dry eye (21%), and skin reactions (19%). Adverse reactions occurred across all age groups, and were generally managed with dose reductions and treatment interruptions. There was an increased incidence of infusion-related reactions in patients aged 65 years and older compared to younger patients (35% vs. 19%).

Infertility: Based on findings in animal studies, BLENREP may impair fertility in females and males. The effects were not evaluated in humans. Pregnancy testing is recommended for females of reproductive potential prior to initiating BLENREP.

Pregnancy Testing: Pregnancy testing is recommended for females of reproductive potential prior to initiating BLENREP.

There are no available data on the use of BLENREP in pregnant women to evaluate for drug-associated risk. No animal reproduction studies were conducted with BLENREP.

Breastfeeding: There is no data on the presence of belantamab mafodotin-blmf in human milk or the effects on the breastfed child. Advise women not to breastfeed during treatment with BLENREP and for 3 months after the last dose.

BCMA: B-cell maturation antigen


About BCMA

BLENREP is a modified antibody that targets BCMA. BCMA is a receptor found on the surface of multiple myeloma cells and is involved in the growth and uncontrolled proliferation of multiple myeloma cells.

Important Safety Information

Of the patients with decreased visual acuity of 20/200 or worse, all resolved and the median duration was 22 days (range: 15 days to 8.3 months).

The most common adverse reactions (≥20%) were keratopathy (71%), decreased visual acuity (53%), nausea (24%), blurred vision (21%), dry eye (21%), and skin reactions (19%). Adverse reactions occurred across all age groups, and were generally managed with dose reductions and treatment interruptions. There was an increased incidence of infusion-related reactions in patients aged 65 years and older compared to younger patients (35% vs. 19%).

Infertility: Based on findings in animal studies, BLENREP may impair fertility in females and males. The effects were not evaluated in humans. Pregnancy testing is recommended for females of reproductive potential prior to initiating BLENREP.

Pregnancy Testing: Pregnancy testing is recommended for females of reproductive potential prior to initiating BLENREP.

There are no available data on the use of BLENREP in pregnant women to evaluate for drug-associated risk. No animal reproduction studies were conducted with BLENREP.

Breastfeeding: There is no data on the presence of belantamab mafodotin-blmf in human milk or the effects on the breastfed child. Advise women not to breastfeed during treatment with BLENREP and for 3 months after the last dose.